| [1] |
CAREY I, D'ANTIGA L, BANSAL S, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: A longitudinal study of vertically hepatitis B virus-infected children on combined therapy[J]. J Virol, 2011, 85(5): 2416-2428. DOI: 10.1128/JVI.01449-10.
|
| [2] |
KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
|
| [3] |
CHEN CF, LEE WC, YANG HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma[J]. Gastroenterology, 2011, 141(4): 1240-1248. DOI: 10.1053/j.gastro.2011.06.036.
|
| [4] |
LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741.
|
| [5] |
JEON MY, KIM BK, LEE JS, et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B[J]. Clin Mol Hepatol, 2020. DOI: 10.3350/cmh.2020.0216. [Online ahead of print]
|
| [6] |
HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724.
|
| [7] |
BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199.
|
| [8] |
LIAW YF, BRUNETTO MR, HADZIYANNIS S. The natural history of chronic HBV infection and geographical differences[J]. Antivir Ther, 2010, 15(Suppl 3): 25-33. DOI: 10.3851/IMP1621.
|
| [9] |
ANDREANI T, SERFATY L, MOHAND D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: Histologic findings and outcome[J]. Clin Gastroenterol Hepatol, 2007, 5(5): 636-641. DOI: 10.1016/j.cgh.2007.01.005.
|
| [10] |
BEASLEY RP, HWANG LY, LIN CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan[J]. Lancet, 1981, 2(8256): 1129-1133. DOI: 10.1016/s0140-6736(81)90585-7.
|
| [11] |
BEASLEY RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: Epidemiologic considerations[J]. Hepatology, 1982, 2(1): 21s-26s. http://www.researchgate.net/publication/284147628_Hepatitis_B_virus_as_the_etiologic_agent_in_hepatocellular_carcinoma
|
| [12] |
CHAN HL, WONG VW, WONG GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. Hepatology, 2010, 52(4): 1232-1241. DOI: 10.1002/hep.23803.
|
| [13] |
CORNBERG M, WONG VW, LOCARNINI S, et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol, 2017, 66(2): 398-411. DOI: 10.1016/j.jhep.2016.08.009.
|
| [14] |
CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA[J]. Gastroenterology, 2014, 146(5): 1240-1248. DOI: 10.1053/j.gastro.2014.01.044.
|
| [15] |
ZHU S, ZHANG H, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037.
|
| [16] |
SOKAL EM, PAGANELLI M, WIRTH S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: Consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition[J]. J Hepatol, 2013, 59(4): 814-829. DOI: 10.1016/j.jhep.2013.05.016.
|
PDF下载 ( 1865 KB)
本文二维码
下载:
